Protagonist Therapeutics (PTGX) EBIT Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) posted EBIT Margin of 6.47% for Q1 2026, up 99.04% sequentially from 677.09% in Q4 2025, and up 6171.0% YoY from 0.1% in Q1 2025.
Protagonist Therapeutics (PTGX) EBIT Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics has reported EBIT Margin for 10 years, with the latest figure at 6.47% in Q1 2026.
- Quarterly EBIT Margin rose 6171.0% year-over-year to 6.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 192.36% (down 20582.0% YoY) and the FY2025 annual result came in at 343.63%, down 40184.0% from the prior year.
- EBIT Margin advanced to 6.47% in Q1 2026 per PTGX's latest filing, from 677.09% in the prior quarter.
- Over five years, EBIT Margin peaked at 80.92% in Q1 2024 and troughed at 4824.56% in Q2 2022.
- A 5-year average of 751.28% and a median of 379.58% in 2022 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 30605 bps in 2022, down 346112 bps in 2022.
- Over 5 years, EBIT Margin stood at 4824.56% in 2022, then surged by 101 bps to 46.1% in 2023, then surged by 67 bps to 76.84% in 2024, then sank by 981 bps to 677.09% in 2025, then jumped by 99 bps to 6.47% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 6.47%, 677.09%, and 985.17% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 74.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.37% |
| Mar 31, 2026 | -6.47% |
| Dec 31, 2025 | -677.09% |
| Sep 30, 2025 | -985.17% |
| Jun 30, 2025 | -758.04% |
| Mar 31, 2025 | -68.18% |
| Dec 31, 2024 | 76.84% |
| Sep 30, 2024 | -886.70% |
| Jun 30, 2024 | -930.96% |
| Mar 31, 2024 | 80.92% |
| Dec 31, 2023 | 46.10% |
| Jun 30, 2022 | -4,824.56% |
| Mar 31, 2022 | -82.07% |
| Dec 31, 2021 | -429.57% |
| Sep 30, 2021 | -329.83% |
| Jun 30, 2021 | -1,363.44% |
| Mar 31, 2021 | -388.12% |
| Dec 31, 2020 | -333.27% |
| Sep 30, 2020 | -59.26% |
| Jun 30, 2020 | -293.02% |